NCT05635149 is a clinical trial of radiotherapy in Colorectal Adenocarcinoma, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05635149?

Interventions in NCT05635149: radiotherapy.

What condition does NCT05635149 study?

NCT05635149 studies Colorectal Adenocarcinoma.

Is NCT05635149 still recruiting?

NCT05635149 is currently status unknown. Last updated 2 December 2022.

Last reviewed 2022-12-02 · How we verify

NCT05635149

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Status unknown Last updated 2 December 2022

What this trial tests

trial testing radiotherapy in Colorectal Adenocarcinoma in 100 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
30 June 2023

30 September 2023

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 January 2022
Primary completion	30 June 2023
Estimated completion	30 September 2023
Sites	1 location across China

Drugs / interventions tested

radiotherapy — full drug profile →

Conditions studied

Colorectal Adenocarcinoma — all drugs for Colorectal Adenocarcinoma →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Colorectal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was an observational cohort study to investigate the efficacy predictors of fuquinitinib combined with anti-PD-1 monoclonal antibody for third-line treatment and above in Chinese patients with advanced colorectal cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target.
Zhang M, Liu J, Xia Q. · · 2023 · cited 77× · PMID 37770953 · DOI 10.1186/s40164-023-00442-x
Exploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis.
Sevcikova A, Mladosievicova B, Mego M, Ciernikova S. · · 2023 · cited 17× · PMID 38139030 · DOI 10.3390/ijms242417199
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.
Ciernikova S, Sevcikova A, Novisedlakova M, Mego M. · · 2024 · cited 9× · PMID 39766170 · DOI 10.3390/cancers16244271
Microsatellite Instability in the Tumor Microenvironment: The Role of Inflammation and the Microbiome.
Vargas-Castellanos E, Rincón-Riveros A. · · 2025 · cited 7× · PMID 40231893 · DOI 10.1002/cam4.70603
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study.
Cheng M, Jin M, Yang S, Zhao L, et al · · 2025 · cited 7× · PMID 39755582 · DOI 10.1136/jitc-2024-009415
Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
Ding Y, Weng S, Zhu N, Mi M, et al · · 2023 · cited 2× · PMID 38058653 · DOI 10.1016/j.heliyon.2023.e22092

Verify or expand the search:

Other trials of radiotherapy

Trials testing the same drug.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07282483 — Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer P · Phase 2 · recruiting
NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting

Other recruiting trials for Colorectal Adenocarcinoma

Currently open trials in the same condition.

NCT06955767 — Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes · NA · recruiting
NCT07407465 — Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal · Phase 2 · recruiting
NCT06951503 — AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer · Phase 3 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT06225011 — Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer · Phase 1 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05635149 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 2 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05635149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing